Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva

Yuan James Rao, Comron Hassanzadeh, Anupama Chundury, Caressa Hui, Barry A. Siegel, Farrokh Dehdashti, Todd DeWees, Daniel Mullen, Matthew A. Powell, David G. Mutch, Julie K. Schwarz, Perry W. Grigsby

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background/purpose The aim of this study was to investigate the use of post-treatment F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for vulvar cancer and compare metabolic response to clinical outcomes. Materials/methods This retrospective study included 21 patients with vulvar squamous cell carcinoma treated with curative-intent radiation between 2007 and 2015. All patients received intensity-modulated radiation treatment (IMRT), a pre-treatment FDG/PET-CT, and a post-treatment FDG-PET/CT performed at a median time of 3 months post-IMRT. Results Median follow-up time was 28 months. Post-treatment FDG-PET/CT demonstrated no evidence of disease (NED) in 12 patients and residual or progressive disease (PD) in 9. FDG-PET/CT response significantly correlated with biopsy-proven locoregional failure (p = 0.02) and was the only significant factor associated with overall survival (OS) (p = 0.049). Patients with NED on FDG-PET had a 2-year locoregional control (LRC) of 89% versus 25% for those with PD (p < 0.01). Patients with NED on FDG-PET/CT had a 2-year OS of 100% versus 42% for those with PD (p = 0.02). FDG-PET/CT evaluation had a sensitivity of 100% and a specificity of 71% for detecting pathologically proven residual disease in patients receiving neoadjuvant or definitive radiation. Conclusion In this single-institution study of women with vulvar cancer, post-treatment response on FDG-PET/CT was associated with LRC and OS.

Original languageEnglish (US)
Pages (from-to)445-451
Number of pages7
JournalRadiotherapy and Oncology
Volume122
Issue number3
DOIs
StatePublished - Mar 1 2017
Externally publishedYes

Fingerprint

Vulva
Positron-Emission Tomography
Squamous Cell Carcinoma
Radiotherapy
Survival
Radiation
Vulvar Neoplasms
Therapeutics
Positron Emission Tomography Computed Tomography
Fluorodeoxyglucose F18
Retrospective Studies
Biopsy

Keywords

  • FDG-PET
  • Radiation
  • Squamous cell carcinoma
  • Vulvar cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva. / Rao, Yuan James; Hassanzadeh, Comron; Chundury, Anupama; Hui, Caressa; Siegel, Barry A.; Dehdashti, Farrokh; DeWees, Todd; Mullen, Daniel; Powell, Matthew A.; Mutch, David G.; Schwarz, Julie K.; Grigsby, Perry W.

In: Radiotherapy and Oncology, Vol. 122, No. 3, 01.03.2017, p. 445-451.

Research output: Contribution to journalArticle

Rao, YJ, Hassanzadeh, C, Chundury, A, Hui, C, Siegel, BA, Dehdashti, F, DeWees, T, Mullen, D, Powell, MA, Mutch, DG, Schwarz, JK & Grigsby, PW 2017, 'Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva', Radiotherapy and Oncology, vol. 122, no. 3, pp. 445-451. https://doi.org/10.1016/j.radonc.2016.12.019
Rao, Yuan James ; Hassanzadeh, Comron ; Chundury, Anupama ; Hui, Caressa ; Siegel, Barry A. ; Dehdashti, Farrokh ; DeWees, Todd ; Mullen, Daniel ; Powell, Matthew A. ; Mutch, David G. ; Schwarz, Julie K. ; Grigsby, Perry W. / Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva. In: Radiotherapy and Oncology. 2017 ; Vol. 122, No. 3. pp. 445-451.
@article{4bb74edf00fc4909912ad7938c095df8,
title = "Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva",
abstract = "Background/purpose The aim of this study was to investigate the use of post-treatment F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for vulvar cancer and compare metabolic response to clinical outcomes. Materials/methods This retrospective study included 21 patients with vulvar squamous cell carcinoma treated with curative-intent radiation between 2007 and 2015. All patients received intensity-modulated radiation treatment (IMRT), a pre-treatment FDG/PET-CT, and a post-treatment FDG-PET/CT performed at a median time of 3 months post-IMRT. Results Median follow-up time was 28 months. Post-treatment FDG-PET/CT demonstrated no evidence of disease (NED) in 12 patients and residual or progressive disease (PD) in 9. FDG-PET/CT response significantly correlated with biopsy-proven locoregional failure (p = 0.02) and was the only significant factor associated with overall survival (OS) (p = 0.049). Patients with NED on FDG-PET had a 2-year locoregional control (LRC) of 89{\%} versus 25{\%} for those with PD (p < 0.01). Patients with NED on FDG-PET/CT had a 2-year OS of 100{\%} versus 42{\%} for those with PD (p = 0.02). FDG-PET/CT evaluation had a sensitivity of 100{\%} and a specificity of 71{\%} for detecting pathologically proven residual disease in patients receiving neoadjuvant or definitive radiation. Conclusion In this single-institution study of women with vulvar cancer, post-treatment response on FDG-PET/CT was associated with LRC and OS.",
keywords = "FDG-PET, Radiation, Squamous cell carcinoma, Vulvar cancer",
author = "Rao, {Yuan James} and Comron Hassanzadeh and Anupama Chundury and Caressa Hui and Siegel, {Barry A.} and Farrokh Dehdashti and Todd DeWees and Daniel Mullen and Powell, {Matthew A.} and Mutch, {David G.} and Schwarz, {Julie K.} and Grigsby, {Perry W.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.radonc.2016.12.019",
language = "English (US)",
volume = "122",
pages = "445--451",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva

AU - Rao, Yuan James

AU - Hassanzadeh, Comron

AU - Chundury, Anupama

AU - Hui, Caressa

AU - Siegel, Barry A.

AU - Dehdashti, Farrokh

AU - DeWees, Todd

AU - Mullen, Daniel

AU - Powell, Matthew A.

AU - Mutch, David G.

AU - Schwarz, Julie K.

AU - Grigsby, Perry W.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background/purpose The aim of this study was to investigate the use of post-treatment F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for vulvar cancer and compare metabolic response to clinical outcomes. Materials/methods This retrospective study included 21 patients with vulvar squamous cell carcinoma treated with curative-intent radiation between 2007 and 2015. All patients received intensity-modulated radiation treatment (IMRT), a pre-treatment FDG/PET-CT, and a post-treatment FDG-PET/CT performed at a median time of 3 months post-IMRT. Results Median follow-up time was 28 months. Post-treatment FDG-PET/CT demonstrated no evidence of disease (NED) in 12 patients and residual or progressive disease (PD) in 9. FDG-PET/CT response significantly correlated with biopsy-proven locoregional failure (p = 0.02) and was the only significant factor associated with overall survival (OS) (p = 0.049). Patients with NED on FDG-PET had a 2-year locoregional control (LRC) of 89% versus 25% for those with PD (p < 0.01). Patients with NED on FDG-PET/CT had a 2-year OS of 100% versus 42% for those with PD (p = 0.02). FDG-PET/CT evaluation had a sensitivity of 100% and a specificity of 71% for detecting pathologically proven residual disease in patients receiving neoadjuvant or definitive radiation. Conclusion In this single-institution study of women with vulvar cancer, post-treatment response on FDG-PET/CT was associated with LRC and OS.

AB - Background/purpose The aim of this study was to investigate the use of post-treatment F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for vulvar cancer and compare metabolic response to clinical outcomes. Materials/methods This retrospective study included 21 patients with vulvar squamous cell carcinoma treated with curative-intent radiation between 2007 and 2015. All patients received intensity-modulated radiation treatment (IMRT), a pre-treatment FDG/PET-CT, and a post-treatment FDG-PET/CT performed at a median time of 3 months post-IMRT. Results Median follow-up time was 28 months. Post-treatment FDG-PET/CT demonstrated no evidence of disease (NED) in 12 patients and residual or progressive disease (PD) in 9. FDG-PET/CT response significantly correlated with biopsy-proven locoregional failure (p = 0.02) and was the only significant factor associated with overall survival (OS) (p = 0.049). Patients with NED on FDG-PET had a 2-year locoregional control (LRC) of 89% versus 25% for those with PD (p < 0.01). Patients with NED on FDG-PET/CT had a 2-year OS of 100% versus 42% for those with PD (p = 0.02). FDG-PET/CT evaluation had a sensitivity of 100% and a specificity of 71% for detecting pathologically proven residual disease in patients receiving neoadjuvant or definitive radiation. Conclusion In this single-institution study of women with vulvar cancer, post-treatment response on FDG-PET/CT was associated with LRC and OS.

KW - FDG-PET

KW - Radiation

KW - Squamous cell carcinoma

KW - Vulvar cancer

UR - http://www.scopus.com/inward/record.url?scp=85008473102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008473102&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2016.12.019

DO - 10.1016/j.radonc.2016.12.019

M3 - Article

C2 - 28063696

AN - SCOPUS:85008473102

VL - 122

SP - 445

EP - 451

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 3

ER -